MedTrace Logo

A Study of Incidence, Treatment Patterns, and Outcomes in Transfusion-dependent Lower-risk Myelodysplastic Syndromes in Spain

NCT07465029 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 1300

Last updated 2026-03-11

No results posted yet for this study

Summary

The purpose of this study is to understand the incidence of transfusion dependent lower-risk myelodysplastic syndromes (TD LR-MDS) and describing real-world first-line treatment patterns, healthcare resource utilization, and associated clinical outcomes in adult patients with TD LR-MDS in Spain

Conditions

  • Lower-risk Myelodysplastic Syndromes (TD LR-MDS)

Interventions

DRUG

Erythropoiesis-stimulating agents (ESAs)

According to the product label

BIOLOGICAL

Luspatercept

According to the product label

DRUG

Lenalidomide

According to the product label

DRUG

Hypomethylating agents (HMAs)

According to the product label

BIOLOGICAL

Reb blood cell transfusion

According to the product label

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-02-02
Primary Completion
2026-03-31
Completion
2026-05-31
FDA Drug
Yes

Countries

  • Spain

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07465029 on ClinicalTrials.gov